Janus Henderson Group (NYSE:JHG) is making a major play for the fast-growing model portfolio market, announcing Friday its acquisition of Richard Bernstein Advisors (RBA), a New York-based firm overseeing approximately $20 billion in assets.
Bausch Health Companies (NYSE:BHC) today announced results from its global Phase 3 RED-C clinical program evaluating amorphous-rifaximin SSD for the primary prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.
Sanara MedTech (NASDAQ:SMTI) announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with initial guidance for 2026.
In times of uncertainty, we often look for something solid to hold onto. Lately, it seems the world’s investors have decided that “something solid” is, quite literally, gold.
The metal’s soaring price is more than just a market trend; it's a global barometer of anxiety.
When faith in currencies, governments, and traditional financial systems begins to waver, we see a familiar flight to the perceived safety of this timeless asset.
Well, pull out the party hats and dust off the stock tickers.
Lithium, the commodity that investors and analysts had all but left for dead in the great market purge of 2023-2024, is back.
The stock market has long treated Tesla (NASDAQ:TSLA) less as a traditional automaker and more as a futuristic technology cult, with its valuation soaring on the gravitational pull of its CEO, Elon Musk.
This persistent "Musk Premium" has burned countless short-sellers.
Bitcoin has vaporised more than US$800 billion in its latest crash and sucked US$1 trillion out of the broader crypto market.
With nearly US$2 trillion in market value and rising allocations from Wall Street firms, ETFs, pension funds, and insurers, Bitcoin is increasingly woven into traditional finance.
Japan’s bond market has been sliding all week, with the 10-year yield now near 2.37% and the 40-year pushing above 4.2%, both multi-decade highs.
U.S. President Donald Trump has escalated his confrontation with European leaders on the eve of the World Economic Forum in Davos, threatening to impose a 200% tariff on French wine and champagne.
If you think the Formula 1 season finale in Abu Dhabi is just about who gets to spray the rose water, you aren’t looking at the balance sheet.
As the sun sets over the Yas Marina Circuit this weekend, we aren’t just witnessing a sporting event; we are watching the closing bell of one of the most efficient capital-generating machines in modern sports.
SLB (NYSE:SLB) today reported financial results for the fourth quarter and full year ended December 31, 2025, reflecting sequential improvement driven by international activity and offshore growth despite softer year-over-year comparisons.
McLean, Virginia-based Booz Allen Hamilton Holding Corporation (NYSE: BAH) announced financial results for its third quarter of fiscal 2026 ended December 31, 2025.
Bausch Health Companies (NYSE:BHC) today announced results from its global Phase 3 RED-C clinical program evaluating amorphous-rifaximin SSD for the primary prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.
Alaska Air Group (NYSE:ALK) delivered a resilient finish to a turbulent 2025, posting fourth-quarter adjusted earnings of $0.43 per share—sharply higher than the $0.10 internal guidance issued just weeks ago.
ImmunityBio (NASDAQ:IBRX) reported updated Phase 2 clinical results for its novel immunotherapy combination in patients with recurrent glioblastoma, suggesting the treatment may overcome the "immune collapse" that typically follows standard cancer therapies.
Ericsson (NASDAQ:ERIC) reported fourth-quarter earnings that surpassed Wall Street projections on Friday, signaling that the Swedish telecommunications giant’s focus on high-margin software and operational efficiency is paying off despite a broader slowdown in network equipment demand.
Beijing has intensified its scrutiny of Meta Platforms (NASDAQ:META) $2 billion acquisition of Chinese-founded agentic AI startup Manus, expanding the probe beyond initial concerns over technology export and national security rules to include potential violations of cross-border currency controls, tax accounting standards, and overseas investment regulations, according to people familiar with the matter.
OKYO Pharma (NASDAQ:OKYO) announced that the U.S. Food and Drug Administration has authorized a single-patient expanded access Investigational New Drug application (IND 176297) for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).